What makes a good antibody–drug conjugate?

Bispecific Antibodies and Antibody–Drug Conjugates for Cancer Therapy: Technological Considerations

(2020) Hyunbo Shim   Biomolecules

Analytical Comparison of Antibody-drug Conjugates Based on Good Manufacturing Practice Strategies

(2020) Zhala TAWFIQ et al.   ANALYTICAL SCIENCES

p38gamma MAPK is essential for aerobic glycolysis and pancreatic tumorigenesis

(2020) Fang Wang et al.   CANCER RESEARCH

Advances in oligonucleotide drug delivery

(2020) Thomas C. Roberts et al.   NATURE REVIEWS DRUG DISCOVERY

Antibody–Drug Conjugates: The Last Decade

(2020) Nicolas Joubert et al.   Pharmaceuticals

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

(2019) Shanu Modi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Resistance to Antibody–Drug Conjugates

(2018) Sara García-Alonso et al.   CANCER RESEARCH

Challenges and new frontiers in analytical characterization of antibody-drug conjugates

(2018) Anil Wagh et al.   mAbs

Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs

(2017) Julian Andreev et al.   MOLECULAR CANCER THERAPEUTICS

Strategies and challenges for the next generation of antibody–drug conjugates

(2017) Alain Beck et al.   NATURE REVIEWS DRUG DISCOVERY

Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy

(2017) Christian Kellner et al.   TRANSFUSION MEDICINE AND HEMOTHERAPY

Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs)

(2017) Ricarda M. Hoffmann et al.   OncoImmunology

Combining antibody–drug conjugates and immune-mediated cancer therapy: What to expect?

(2016) Hans-Peter Gerber et al.   BIOCHEMICAL PHARMACOLOGY

A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy

(2016) John Y. Li et al.   CANCER CELL

Antibody-siRNA conjugates: drugging the undruggable for anti-leukemic therapy

(2016) Jogender Tushir-Singh   EXPERT OPINION ON BIOLOGICAL THERAPY

Cutting-edge mass spectrometry methods for the multi-level structural characterization of antibody-drug conjugates

(2016) Alain Beck et al.   Expert Review of Proteomics

Linkers Having a Crucial Role in Antibody–Drug Conjugates

(2016) Jun Lu et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Pharmacokinetics and pharmacodynamics of DSTA4637A: A novel THIOMAB™ antibody antibiotic conjugate against Staphylococcus aureus in mice

(2016) Chenguang Zhou et al.   mAbs

ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies

(2016) M. J. Flynn et al.   MOLECULAR CANCER THERAPEUTICS

Targeted Activation of Toll-Like Receptors: Conjugation of a Toll-Like Receptor 7 Agonist to a Monoclonal Antibody Maintains Antigen Binding and Specificity

(2015) Adam J. R. Gadd et al.   BIOCONJUGATE CHEMISTRY

Site-Specific Antibody–Drug Conjugates: The Nexus of Bioorthogonal Chemistry, Protein Engineering, and Drug Development

(2015) Paresh Agarwal et al.   BIOCONJUGATE CHEMISTRY

Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics

(2015) Eunhee G. Kim et al.   Biomolecules & Therapeutics

Antibody-drug conjugates as novel anti-cancer chemotherapeutics

(2015) C. Peters et al.   BIOSCIENCE REPORTS

A Polymer-Based Antibody-Vinca Drug Conjugate Platform: Characterization and Preclinical Efficacy

(2015) A. V. Yurkovetskiy et al.   CANCER RESEARCH

Development of a quantitative mass spectrometry multi-attribute method for characterization, quality control testing and disposition of biologics

(2015) Richard S Rogers et al.   mAbs

Nanobody-based cancer therapy of solid tumors

(2015) Marta Kijanka et al.   Nanomedicine

Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index

(2015) Robert P Lyon et al.   NATURE BIOTECHNOLOGY

Insights on the immunogenicity of antibody–drug conjugates

(2015) Montserrat Carrasco-Triguero   Bioanalysis

A Mechanistic Tumor Penetration Model to Guide Antibody Drug Conjugate Design

(2015) Christina Vasalou et al.   PLoS One

Immunogenicity of Antibody Drug Conjugates: Bioanalytical Methods and Monitoring Strategy for a Novel Therapeutic Modality

(2014) M. Benjamin Hock et al.   AAPS Journal

Practical Considerations for the Pharmacokinetic and Immunogenic Assessment of Antibody–Drug Conjugates

(2014) Melody Sauerborn et al.   BIODRUGS

Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma

(2014) Y.-T. Tai et al.   BLOOD

Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates

(2014) Robert P Lyon et al.   NATURE BIOTECHNOLOGY

IgG Subclasses and Allotypes: From Structure to Effector Functions

(2014) Gestur Vidarsson et al.   Frontiers in Immunology

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia

(2013) S. H. Petersdorf et al.   BLOOD

Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates

(2013) Michael Ritchie et al.   mAbs

Site-specific antibody drug conjugates for cancer therapy

(2013) Siler Panowski et al.   mAbs

Bioanalytical assay strategies for the development of antibody–drug conjugate biotherapeutics

(2013) Surinder Kaur et al.   Bioanalysis

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

(2012) Sunil Verma et al.   NEW ENGLAND JOURNAL OF MEDICINE

Influence of Affinity and Antigen Internalization on the Uptake and Penetration of Anti-HER2 Antibodies in Solid Tumors

(2011) S. I. Rudnick et al.   CANCER RESEARCH

Analytical methods for physicochemical characterization of antibody drug conjugates

(2011) Aditya Wakankar et al.   mAbs

Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug Resistance

(2010) Y. V. Kovtun et al.   CANCER RESEARCH

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index

(2008) Jagath R Junutula et al.   NATURE BIOTECHNOLOGY